Valor202020212022202320242025TTMGastos comerciales, generales y administrativos15.57 M18.21 M22.51 M17.3 M18.17 M18.46 M18.46 MInvestigación y desarrollo12.32 M33.91 M13.99 M15.71 M12.47 M17.73 M17.73 MBeneficio operativo-26.45 M-49.21 M-22.52 M-24.73 M-21.48 M-36.62 M-36.62 MTotal de ingresos no operativos4.52 M5.94 M-3.29 M1.45 M2.9 M-32.03 M-32.03 MGastos por intereses, netos de intereses capitalizados———22 K———Ingresos no operativos, una vez deducidos los gastos por intereses1.64 M4.46 M-1.14 M1.43 M3.57 M-31.9 M-31.9 MIngresos/gastos extraordinarios2.88 M1.49 M-2.15 M-4 000-670 K-132 K-132 KBeneficio antes de impuestos-21.92 M-43.27 M-25.81 M-23.28 M-18.58 M-68.65 M-68.65 MParticipación en los beneficios———————Impuestos-1.24 M0541 K-1.8 M0-5.28 M-7.13 MParticipación minoritaria-36 K-251 K-80 K7 00027 K166 K166 KOtros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-20.65 M-43.02 M-26.27 M-21.49 M-18.61 M-63.53 M-63.53 MOperaciones suspendidas———————Beneficio neto-20.65 M-43.02 M-26.27 M-21.49 M-18.61 M-63.53 M-63.53 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-20.65 M-43.02 M-26.27 M-21.49 M-18.61 M-63.53 M-63.53 MBeneficio básico por acción——-0.15-0.12-0.09-0.28-0.28Beneficio por acción diluido——-0.15-0.12-0.09-0.28-0.28Número medio de acciones ordinarias——169.79 M172.66 M200.19 M230.12 M913.38 MAcciones diluidas——169.79 M172.66 M200.19 M230.12 M913.38 MEBITDA-25.62 M-48.55 M-21.94 M-24.53 M33.54 M-36.56 M-36.56 MEBIT-26.45 M-49.21 M-22.52 M-24.73 M-21.48 M-36.62 M-36.62 MCosto de los ingresos385 K1.43 M728 K671 K334 K——Otros costes de producción———————Amortización y depreciación (flujo de caja)823 K663 K582 K202 K55.02 M59 K59 K
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.